Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2014; 9(03): 130-136
DOI: 10.4103/1793-5482.142732
ORIGINAL ARTICLE

The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study

Maysam Alimohamadi
Department of Neurosurgery, Tehran University of Medical Sciences, Tehran
,
Vahid Ownagh
1   Sina Hospital, Tehran University of Medical Sciences, Tehran
,
Leila Mahouzi
2   Arad Hospital, Tehran University of Medical Sciences, Tehran
,
Afshin Ostovar
3   The Persian Gulf Infectious Diseases and Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr
,
Kazem Abbassioun
4   Department of Neurosurgery, Arad Hospital, Tehran University of Medical Sciences, Tehran
,
Abbas Amirjmshidi
5   Department of Neurosurgery, Sina Hospital, Tehran University of Medical Sciences, Tehran
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Background and Objectives: The tumoral biomarkers have a rather well known effect upon the tumor control period of several types of malignant lesions. The aim of this study was to evaluate the impact of immunohistochemical (IHC) markers of Ki-67 and p53 on the long-term outcome of growth hormone (GH)-secreting pituitary adenomas treated surgically. Materials and Methods: We conducted and followed a cohort of 47 consecutive patients with GH-secreting pituitary adenomas referred to our department during a 4 year period for trans-sphenoidal microsurgical adenomectomy. The expression levels of Ki-67 and p53 were determined by IHC study of the tissue samples. Periodical pituitary magnetic resonance imaging (MRI), visual field studies and hormonal evaluations (GH and insulin-like growth factor-1 [IGF-1]) performed during the follow-up period were the outcome measures. Results: The level of Ki-67 expression was higher among patients with postoperative residual tumor (3.5 vs. 1.7%) and those with a hormonal recurrence (4.3 vs. 1.6%). The p53 expression level was remarkably higher in patients with radiological recurrence (18 vs. 6.3%). Patients with invasive features (i.e. cavernous sinus and suprasellar invasion) had significantly higher p53 and Ki-67 values and higher IGF-1 levels during the follow-up period. The patients younger than 30 years of age and those with mixed GH-prolactin secreting adenomas had significantly higher hormonal remission and lower radiological recurrence rates. Conclusion: Each of the biomarkers, Ki-67 and p53, along with patient's age and mixed GH-prolactin secretion showed a kind of correlation with each of aspects of the clinical, hormonal and radiologic outcome of GH-secreting pituitary adenomas in this series.

Key-words:

Acromegaly - growth hormone - immunohistochemistry - Ki-67 - p53 - pituitary adenoma


Publication History

Article published online:
22 September 2022

© 2014. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India